Mild to moderate side effects such as nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite are commonly associated with the use of semaglutide and liraglutide [10]
By targeting both pathways, tirzepatide produces stronger metabolic effects than GLP-1only medications in many patients
They can provide guidance, explain the medical necessity, and explore alternative treatment options that may be covered by your insurance
This area underscores the microbiome as a central metabolic interface between diet, host genetics, and health outcomes
Buyer Takeaway: GLP-1 medications are clinically substantiated for weight management in appropriate candidates, but they require medical evaluation precisely because the contraindications and side effect profile are real